title: Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region.
abstract: Phosphorothioate oligonucleotides complementary to mRNA of the human cytomegalovirus (HCMV) DNA polymerase gene or to RNA transcripts of the major immediate-early regions 1 and 2 (IE1 and IE2) of HCMV were evaluated for antiviral activity in a 96-well immunoassay with primary human dermal fibroblasts as host cells. Oligonucleotides complementary to RNA of the IE2 region exhibited the most potent antiviral activity. One of these oligonucleotides, ISIS 2922, was at least 30-fold more potent than the nucleoside analog, ganciclovir, with a 50% effective concentration of 0.37 microM in the 96-well immunoassay. In an infectious virus yield reduction assay, ISIS 2922 and ganciclovir reduced production of infectious virus by 2 log units at concentrations of 2.2 and 36 microM, respectively. A control oligonucleotide showed no inhibition of virus production at concentrations as high as 3 microM. ISIS 2922 reduced IE protein synthesis in HCMV-infected cells in a dose-dependent manner which correlated with antiviral activity. The antiviral activity of ISIS 2922 was not due to oligonucleotide-induced cytotoxicity since effects on cell viability or proliferation were observed only at concentrations well in excess of effective antiviral concentrations. The specificity and potency of ISIS 2922 suggest that it may be useful for the treatment of cytomegalovirus disease in humans.
authors.affiliation: Department of Infectious Diseases, Isis Pharmaceuticals, Carlsbad, California 92008.
authors.forename: R F
authors.initials: RF
authors.lastname: Azad
authors.forename: V B
authors.initials: VB
authors.lastname: Driver
authors.forename: K
authors.initials: K
authors.lastname: Tanaka
authors.forename: R M
authors.initials: RM
authors.lastname: Crooke
authors.forename: K P
authors.initials: KP
authors.lastname: Anderson
mesh_terms: D000998:Antiviral Agents / Q000494:pharmacology*; D001483:Base Sequence; D003587:Cytomegalovirus / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism; D003588:Cytopathogenic Effect, Viral / Q000187:drug effects; D004259:DNA-Directed DNA Polymerase / Q000235:genetics; D005347:Fibroblasts / Q000187:drug effects; D017781:Genes, Immediate-Early; D006801:Humans; D007118:Immunoassay; D008826:Microbial Sensitivity Tests; D008969:Molecular Sequence Data; D018075:RNA, Complementary / Q000187:drug effects*; D012367:RNA, Viral / Q000187:drug effects*; D013873:Thionucleotides / Q000494:pharmacology*; D014158:Transcription, Genetic; D010948:Viral Plaque Assay
chemical_list: D000998:Antiviral Agents; D018075:RNA, Complementary; D012367:RNA, Viral; D013873:Thionucleotides; D004259:DNA-Directed DNA Polymerase